Arbutus Biopharma Corp (ABUS) is lower by Friday morning, with the stock falling -1.16% in pre-market trading to 4.26. ABUS's short-term technical score of 36 indicates that the stock has traded less bullishly over the last month than 64% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, Arbutus Biopharma Corp ranks higher than 65% of stocks. Arbutus Biopharma Corp has risen 9.67% over the past month, closing at $3.48 on November 5. During this period of time, the stock fell as low as $3.11 and as high as $6.50. ABUS has an average analyst recommendation of Strong Buy. The company has an average price target of $6.00.
ABUS has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on ABUS!